Opinion|Videos|November 13, 2026

LITESPARK-022: Immature Overall Survival Data and the Added-Toxicity Trade-Off

Desai and Kydd discuss LITESPARK-022's immature overall survival signal (HR 0.78) and the 22% increase in grade 3+ adverse events with belzutifan.


Related to this article